Dew, I will carefully follow QTc-prolongation in the comming abstracts, but I feel you are only looking at the worst case senario. "One of these patients had pre-existing "significant cardiac risk factors and underlying, asymtomatic, severe coronary artery disease."
From a Oxigene PR in 2002.
"One patient with anaplastic thyroid cancer had a complete response and is alive 30 months after the treatment," the article states. Two other patients, one with metastatic colon cancer and the other with metastatic thyroid cancer, experienced prolonged (more than one year) freedom from disease progression.
Dr. Remick and his team found no significant myelotoxicity, stomatitis or alopecia. Researchers noted four episodes of dose-limiting toxicity, including two episodes of acute coronary syndrome. One of these patients had pre-existing "significant cardiac risk factors and underlying, asymtomatic, severe coronary artery disease." In the other patient, EKG changes normalized and there was no elevation of any serum marker indicative of cardiac damage. No cardiac events were observed in the two other completed Phase I studies.
"The drug appears to have demonstrable clinical activity early in its clinical development," the article reports. "Important clinical observations with CA4P include: a lack of traditional cytotoxic effects." The authors conclude that combining this compound with other modalities including cytotoxic drugs, radiation and antiangiogenesis agents will likely be an attractive prospect.
For AMD I pass my comments until I see some trial results.
AI
Market Data 
Markets 
